Company’s 36-month beta value is 1.56.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CRDF is 60.75M, and currently, short sellers hold a 28.46% ratio of that floaft. The average trading volume of CRDF on July 08, 2025 was 1.21M shares.
CRDF) stock’s latest price update
Cardiff Oncology Inc (NASDAQ: CRDF)’s stock price has increased by 8.55% compared to its previous closing price of $3.65. However, the company has seen a 25.77% increase in its stock price over the last five trading sessions. seekingalpha.com reported 2025-06-27 that Cardiff Oncology’s recent trial data readout delay has unnerved the market, but I see this as a potential buying opportunity for speculative investors. Leadership change is not a major risk factor. The new CMO’s pedigree suggests confidence in the company’s prospects ahead of the catalyst. The delay could suggest an attempt to improve poor data, or an ability to add to already strong data by waiting for more patient second scans.
CRDF’s Market Performance
Cardiff Oncology Inc (CRDF) has seen a 25.77% rise in stock performance for the week, with a 9.44% gain in the past month and a 44.07% surge in the past quarter. The volatility ratio for the week is 7.73%, and the volatility levels for the past 30 days are at 7.70% for CRDF. The simple moving average for the last 20 days is 12.24% for CRDF stock, with a simple moving average of 18.53% for the last 200 days.
Analysts’ Opinion of CRDF
Jefferies, on the other hand, stated in their research note that they expect to see CRDF reach a price target of $3.50. The rating they have provided for CRDF stocks is “Hold” according to the report published on June 24th, 2025.
Craig Hallum gave a rating of “Buy” to CRDF, setting the target price at $8 in the report published on September 06th of the previous year.
CRDF Trading at 23.81% from the 50-Day Moving Average
After a stumble in the market that brought CRDF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.75% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRDF starting from Levine James E., who purchase 2,752 shares at the price of $5.42 back on Dec 17 ’24. After this action, Levine James E. now owns 65,316 shares of Cardiff Oncology Inc, valued at $14,905 using the latest closing price.
Levine James E., the Chief Financial Officer of Cardiff Oncology Inc, purchase 2,400 shares at $5.00 during a trade that took place back on Dec 18 ’24, which means that Levine James E. is holding 67,716 shares at $12,000 based on the most recent closing price.
Stock Fundamentals for CRDF
Current profitability levels for the company are sitting at:
- -108.77 for the present operating margin
- 0.58 for the gross margin
The net margin for Cardiff Oncology Inc stands at -102.0. The total capital return value is set at -0.73. Equity return is now at value -74.15, with -61.51 for asset returns.
Based on Cardiff Oncology Inc (CRDF), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -31.52.
Currently, EBITDA for the company is -48.25 million with net debt to EBITDA at 0.44. When we switch over and look at the enterprise to sales, we see a ratio of 507.37. The receivables turnover for the company is 1.18for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.22.
Conclusion
In a nutshell, Cardiff Oncology Inc (CRDF) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
